CGON

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Wall Street analysts forecast CGON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGON is 70.09 USD with a low forecast of 55.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

CG Oncology Inc revenue for the last quarter amounts to 1.67M USD, increased 3774.42 % YoY.

CG Oncology Inc. EPS for the last quarter amounts to -0.57 USD, increased 90.00 % YoY.

CG Oncology Inc (CGON) has 113 emplpoyees as of December 16 2025.

Today CGON has the market capitalization of 3.21B USD.